These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

846 related items for PubMed ID: 29102254

  • 21. Pathological downstaging following radical cystectomy for muscle-invasive bladder cancer: Survival outcomes in the setting of neoadjuvant chemotherapy versus transurethral resection only.
    Cajipe M, Wang H, Elshabrawy A, Kaushik D, Liss M, Svatek R, Wu S, Chowdhury WH, Ramamurthy C, Mansour AM.
    Urol Oncol; 2020 Apr; 38(4):231-239. PubMed ID: 31956078
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy.
    von Landenberg N, Speed JM, Cole AP, Seisen T, Lipsitz SR, Gild P, Menon M, Kibel AS, Roghmann F, Noldus J, Sun M, Trinh QD.
    Urol Oncol; 2018 Feb; 36(2):78.e13-78.e19. PubMed ID: 29169845
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy.
    Krasnow RE, Drumm M, Roberts HJ, Niemierko A, Wu CL, Wu S, Zhang J, Heney NM, Wszolek MF, Blute ML, Feldman AS, Lee RJ, Zietman AL, Shipley WU, Efstathiou JA.
    Eur Urol; 2017 Jul; 72(1):54-60. PubMed ID: 28040351
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC).
    Arcangeli G, Arcangeli S, Strigari L.
    Crit Rev Oncol Hematol; 2015 Apr; 94(1):105-15. PubMed ID: 25541350
    [Abstract] [Full Text] [Related]

  • 29. Trimodal therapy in muscle invasive bladder cancer management.
    Polo-Alonso E, Kuk C, Guruli G, Paul AK, Thalmann G, Kamat A, Solsona E, Thalmann G, Urdaneta AI, Zlotta AR, Mir MC.
    Minerva Urol Nefrol; 2020 Dec; 72(6):650-662. PubMed ID: 33263367
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Outcomes for Muscle-invasive Bladder Cancer with Radical Cystectomy or Trimodal Therapy in US Veterans.
    Kumar A, Cherry DR, Courtney PT, Nalawade V, Kotha N, Riviere PJ, Efstathiou J, McKay RR, Karim Kader A, Rose BS, Stewart TF.
    Eur Urol Open Sci; 2021 Aug; 30():1-10. PubMed ID: 34337540
    [Abstract] [Full Text] [Related]

  • 34. Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer.
    Royce TJ, Feldman AS, Mossanen M, Yang JC, Shipley WU, Pandharipande PV, Efstathiou JA.
    Clin Genitourin Cancer; 2019 Feb; 17(1):23-31.e3. PubMed ID: 30482661
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Survival outcomes of patients with muscle-invasive bladder cancer according to pathological response at radical cystectomy with or without neo-adjuvant chemotherapy: a case-control matching study.
    van Ginkel N, Hermans TJN, Meijer D, Boormans JL, Voortman J, Mertens L, van Beek SC, Vis AN, Dutch Cystectomy Snapshot Research Group.
    Int Urol Nephrol; 2022 Dec; 54(12):3145-3152. PubMed ID: 35997906
    [Abstract] [Full Text] [Related]

  • 37. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients.
    Koga F, Kihara K, Yoshida S, Yokoyama M, Saito K, Masuda H, Fujii Y, Kawakami S.
    BJU Int; 2012 Mar; 109(6):860-6. PubMed ID: 21854531
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.
    Koga F, Fujii Y, Masuda H, Numao N, Yokoyama M, Ishioka J, Saito K, Kawakami S, Kihara K.
    BJU Int; 2012 Sep; 110(6 Pt B):E203-8. PubMed ID: 22289431
    [Abstract] [Full Text] [Related]

  • 40. The importance of clinical stage among patients with a complete pathologic response at radical cystectomy after neoadjuvant chemotherapy.
    Parker WP, Ho PL, Boorjian SA, Melquist JJ, Thapa P, Holzbeierlein JM, Frank I, Kamat AM, Lee EK.
    World J Urol; 2016 Nov; 34(11):1561-1566. PubMed ID: 26943643
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 43.